Advanced NSCLC Trials Demonstrate Potential of First-Line Immunotherapy – GenomeWeb
|
Advanced NSCLC Trials Demonstrate Potential of First-Line Immunotherapy
GenomeWeb These results suggest the anti-PD-1 checkpoint immunotherapy conferred some benefit as a front-line monotherapy, even for advanced NSCLC cases with relatively low levels of PD-L1, Lopes said during an ASCO press briefing over the weekend. |
